DUBLIN, Aug. 25, 2023 /PRNewswire/ — The “Global Skeletal Dysplasia Market (2023-2028) by Type, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
The Global Skeletal Dysplasia Market represents a significant area of interest within the healthcare and pharmaceutical sector. With an estimated value of USD 2.6 billion in 2022, this market is projected to grow to USD 3.66 billion by 2027, exhibiting a Compound Annual Growth Rate (CAGR) of 7.08%.
Skeletal dysplasias, a collection of genetic disorders characterized by abnormal bone and cartilage development, encompass a diverse array of over 450 distinct types.
The global skeletal dysplasia market is dedicated to developing, manufacturing, and disseminating diagnostic tools, treatments, and therapies for individuals affected by skeletal dysplasia.
The overarching goal is to enhance the quality of life and overall outcomes for patients by offering timely and precise diagnoses, supportive care, and potential targeted therapeutic interventions. The market has gained prominence in recent years, driven by increasing awareness, advancements in diagnostics and research technology, and a growing demand for effective interventions and treatments.
Given the wide spectrum of genetic disorders falling under the skeletal dysplasia umbrella, the market encompasses diverse patient populations with varying medical needs and degrees of severity. Approaches to treatment are multifaceted, aiming to improve patients’ quality of life while addressing the specific complications associated with skeletal dysplasia. Supportive care, including physical and occupational therapy, contributes to enhanced mobility and function.
Orthopedic interventions like corrective surgeries and bracing are recommended to address skeletal deformities and enhance posture. Additionally, medications are commonly employed to alleviate symptoms such as pain and respiratory issues.
Recent developments in genetics and biotechnology have sparked the investigation of potential targeted therapies for particular types of skeletal dysplasia. These treatments are meant to treat the underlying genetic flaws and perhaps alter the course of the illness. Targeted therapies are still being developed, so their accessibility and effectiveness may differ depending on the type of skeletal dysplasia.
The market for skeletal dysplasia faces several obstacles. First off, skeletal dysplasia’s heterogeneity makes diagnosis and treatment challenging. Furthermore, there may not be as much knowledge about some types of skeletal dysplasia due to their rarity. Additionally, the high price of targeted therapies and genetic testing may make them inaccessible to some populations, especially in low-income areas.
In the upcoming years, the global market for skeletal dysplasia is anticipated to expand due to rising awareness, developments in genetic research, and potential introductions of targeted therapies. The quality of life for people with skeletal dysplasia will continue to improve thanks to advances in supportive care, orthopedic interventions, and early and accurate diagnosis.
Market Segmentations
HPP dominated the market. FOP is anticipated to grow over the forecast period at a profitable CAGR. The segment is expected to grow over the forecast years due to several factors, including a strong pipeline of products and rising disease awareness.
For instance, patients and their families can learn more about the condition and how to manage it from the International Fibrodysplasia Ossificans Progressive Association (IFOPA). This nonprofit supports people with FOP. IFOPA also contributes financial support to numerous studies to spread knowledge of the condition and discover a treatment.
Surgery held the largest market share due to its superior efficacy in treating conditions like achondroplasia and HPP. One of the key factors anticipated to contribute to the segment’s growth is patients’ rising preference for surgeries. A rising focus on developing novel medications for treating specific types of skeletal dysplasia, such as FOP and MO, is expected to cause the medication segment to grow faster over the forecast period.
Europe dominated the skeletal dysplasia market. The high adoption of operations for treatment and raising awareness of the condition is to blame for the region’s dominance. An extensive diagnostic and research network for skeletal dysplasia is provided by the non-profit European Skeletal Dysplasia Network (ESDD).
Organizations that carry out various epidemiology studies support efforts to increase public awareness of skeletal dysplasia and inform patients and their families about the prevalence and effects of the condition. These elements are fueling the market expansion in this area.
Market Dynamics
Drivers
- Increasing Prevalence of Skeletal Dysplasia
- Presence of Plethora of Products in the Pipeline
- Growth in the Medical Tourism in Developing Economies
Restraints
- High Cost Associated with Branded Drugs
Opportunities
- Increasing R&D of Novel Growth Hormone Products
- Technological Advancements Associated with Skeletal Dysplasia
Challenges
- Prenatal Diagnosis of Skeletal Dysplasias
Market Analysis
- Regulatory Scenario
- Porter’s Five Forces Analysis
- PESTLE Analysis
- Impact of COVID-19
- Ansoff Matrix Analysis
Company Profiles
- Amgen, Inc.
- ARUP Laboratories
- BioMarin Pharmaceutical, Inc.
- CELGENE Corp.
- Cipla, Inc.
- Dr. Reddy’s Laboratories, Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche, Ltd.
- INNOSKEL
- Ipsen Group
- Novartis Ag
- Regeneron Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries, Ltd.
- The Nemours Foundation
For more information about this report visit https://www.researchandmarkets.com/r/k9gpzq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:SOURCE Research and Markets
Featured image: ©